Ignite Creation Date:
2025-12-24 @ 2:07 PM
Ignite Modification Date:
2026-01-03 @ 9:28 PM
Study NCT ID:
NCT02178995
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2014-06-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Methylphenidate Treatment of Attention Deficits in Epilepsy
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D004827', 'term': 'Epilepsy'}, {'id': 'D003072', 'term': 'Cognition Disorders'}, {'id': 'D001289', 'term': 'Attention Deficit Disorder with Hyperactivity'}], 'ancestors': [{'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D019958', 'term': 'Attention Deficit and Disruptive Behavior Disorders'}, {'id': 'D065886', 'term': 'Neurodevelopmental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008774', 'term': 'Methylphenidate'}], 'ancestors': [{'id': 'D010648', 'term': 'Phenylacetates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jadamsuw@stanford.edu', 'phone': '2069144771', 'title': 'Jesse Adams, MD', 'organization': 'Stanford University'}, 'certainAgreement': {'piSponsorEmployee': True}, 'limitationsAndCaveats': {'description': 'Relatively small sample; Control is healthy patients rather than epilepsy patients; Healthy controls improve more on re-testing than epilepsy patients; Single-dose portion does not mirror clinical practice; open-label portion is not blinded.'}}, 'adverseEventsModule': {'timeFrame': 'During entirety of pt participation (~2 months), throughout entirety of study.', 'description': 'Commonly-expected side effects (anxiety, tachycardia) were routinely asked about at the end of participant visits, and responses recorded. Vital signs were checked at visits 1, 4, and 5. Fatigue was reported spontaneously by the affected participant and was not assessed routinely.', 'eventGroups': [{'id': 'EG000', 'title': 'Participants With Epilepsy (Open-label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.', 'otherNumAtRisk': 30, 'otherNumAffected': 2, 'seriousNumAtRisk': 30, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo, 20mg, Then 10mg (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\nPlacebo, 20mg of methylphenidate, 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 6, 'otherNumAffected': 0, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Placebo, 10mg, Then 20mg (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\nPlacebo, 10mg of methylphenidate, 20mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': '10mg, 20mg, Then Placebo (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\n10mg of methylphenidate, 20mg of methylphenidate, Placebo.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 5, 'otherNumAffected': 0, 'seriousNumAtRisk': 5, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': '10mg, Placebo, Then 20mg (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\n10mg of methylphenidate, Placebo, 20mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': '20mg, 10mg, Then Placebo (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\n20mg of methylphenidate, 10mg of methylphenidate, Placebo.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': '20mg, Placebo, Then 10mg (Double-blind)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules in the following order:\n\n20mg of methylphenidate, Placebo, 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'otherNumAtRisk': 5, 'otherNumAffected': 0, 'seriousNumAtRisk': 5, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': '40mg, 20mg, Then Placebo (One Participant)', 'description': 'This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.', 'otherNumAtRisk': 1, 'otherNumAffected': 1, 'seriousNumAtRisk': 1, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Healthy Controls', 'description': 'Healthy controls will complete the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but will not be exposed to study medication. They are included as a control group for the open-label phase of the study (visit 1 vs visit 5) only.', 'otherNumAtRisk': 15, 'otherNumAffected': 0, 'seriousNumAtRisk': 15, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Anxiety/panic attack', 'notes': 'Four participants experienced a period of anxiety following ingestion of medication, lasting 1-3 hours, without other symptoms. Vitals were stable, and symptoms resolved on their own. Two of the four elected to withdraw.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 30, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 1, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tachycardia', 'notes': '\\~4 hours after dose had 2-3 hours of HR \\~160bpm w/ no other symptoms. Resolved w/ no intervention. No other symptoms. BP stable per pt report. Pt did not seek care. We withdrew pt.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 30, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 1, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Increased anxiety', 'notes': 'One participant reported increased anxiety after having tolerated all of the blinded capsules in the randomized portion. This participant elected to withdraw from the open- label portion.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 30, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 1, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fatigue', 'notes': 'One participant tolerated all three randomized doses, yet experienced fatigue on the open-label dose. This participant elected to withdraw from the open-label trial.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 30, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 1, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': "Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables)", 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'title': "D'", 'categories': [{'measurements': [{'value': '-3.3', 'spread': '0.9', 'groupId': 'OG000'}, {'value': '-3.58', 'spread': '0.78', 'groupId': 'OG001'}, {'value': '-3.66', 'spread': '0.77', 'groupId': 'OG002'}]}]}, {'title': 'HRTSD', 'categories': [{'measurements': [{'value': '0.19', 'spread': '0.048', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '0.034', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '0.036', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.037', 'groupIds': ['OG000', 'OG001', 'OG002'], 'pValueComment': 'HRTSD p-value = 0.037; p \\< 0.05 considered significant', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Within-subjects contrasts, n=31, df=1'}, {'pValue': '0.055', 'groupIds': ['OG000', 'OG001', 'OG002'], 'pValueComment': "D' p = 0.055. p \\< 0.05 considered significant.", 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'Within-subjects contrasts, placebo v 10mg v 20mg.'}, {'pValue': '0.758', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'HRTSD 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.499', 'groupIds': ['OG001', 'OG002'], 'groupDescription': "d' 10mg vs 20mg", 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'difference in scores on specific variables between MPH 20mg, 10mg, and placebo (randomized to administration at weeks 2, 3, or 4)', 'description': "Scores on this test measure attentiveness/vigilance and response time. Primary measures are: D', HRTSD D' represents 'detectability,' and is a derived statistic which measures a participant's ability to distinguish target stimuli from non-target stimuli, and incorporates response time and accuracy factors. The equation for deriving it is proprietary to the test which markets the CPT. A higher, or less negative, score is considered WORSE.\n\nHRTSD represents the standard deviation of participant hit reaction time data, as measured for a variety of different stimuli types across the trial. It is a measure of the participant's ability to maintain attention across the trial. A higher score represents more variability and is considered WORSE.", 'unitOfMeasure': 'Units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Symbol-digit Matching Test (Double-blind Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'categories': [{'measurements': [{'value': '49.8', 'spread': '11.9', 'groupId': 'OG000'}, {'value': '52.2', 'spread': '11.6', 'groupId': 'OG001'}, {'value': '50.6', 'spread': '11.3', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.008', 'groupIds': ['OG000', 'OG001', 'OG002'], 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.071', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'SDMT 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Difference in scores between MPH 20mg, 10mg, or placebo during double-blind portion during which medication was randomized to weeks 2, 3, or 4.', 'description': "Symbol-digit matching test is a measure processing speed and working memory. The task involves matching nonsense symbols with numbers based on a key as quickly as possible within 90s. Score represents the number of correct responses within the time frame. Minimum score is 0. There is not a meaningful 'maximum' score, as there are too many symbols for a participant to successfully complete within the allotted time. A higher score is better.", 'unitOfMeasure': 'points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'MCG Paragraph Memory Test (Double-blind Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'categories': [{'measurements': [{'value': '25.2', 'spread': '14.8', 'groupId': 'OG000'}, {'value': '27.4', 'spread': '15.4', 'groupId': 'OG001'}, {'value': '28', 'spread': '15.3', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.154', 'groupIds': ['OG000', 'OG001', 'OG002'], 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.779', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'MCG 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Difference in scores between MPH 20mg, 10mg, or placebo, randomized to be given at weeks 2, 3, or 4', 'description': 'MCG paragraph memory test is a measure of verbal memory. Participants are read aloud a long, detailed story, and are then asked to immediately repeat all information they can remember from the story. Each pertinent story element (as pre-defined on a key) is considered 1 correct response. Minimum score is 0, maximum is 100. A higher score is better.', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Conners CPT Outcomes (Primary Variables) (Open-Label Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'title': 'HRTSD', 'categories': [{'measurements': [{'value': '0.22', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '0.16', 'spread': '0.03', 'groupId': 'OG001'}, {'value': '0.20', 'spread': '0.04', 'groupId': 'OG002'}, {'value': '0.15', 'spread': '0.03', 'groupId': 'OG003'}]}]}, {'title': "D'", 'categories': [{'measurements': [{'value': '-2.9', 'spread': '0.9', 'groupId': 'OG000'}, {'value': '-3.8', 'spread': '0.7', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '0.5', 'groupId': 'OG002'}, {'value': '-4.2', 'spread': '0.8', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'HRTSD P\\<0.0001', 'groupDescription': 'Intra-group comparison, HRTSD', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.001', 'groupIds': ['OG002', 'OG003'], 'pValueComment': 'HRTSD p \\<0.001 for healthy controls', 'groupDescription': 'Intra-group comparison, HRTSD, healthy controls', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.322', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Between-group comparisons by 2-way ANOVA, HRTSD', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': "Intra-group comparison, epilepsy, D'", 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.037', 'groupIds': ['OG002', 'OG003'], 'groupDescription': "Intra-group analysis, healthy controls, d'", 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.08', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': "Intra-group analysis by 2-way ANOVA, d'", 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Difference between scores at baseline (visit 1) and on methylphenidate open-label (visit 5), compared to untreated healthy controls', 'description': "Within-groups comparison (between visit 1 and visit 5 within patients with epilepsy, comparing scores at baseline to scores on methylphenidate) as well as a comparison against healthy controls who repeated the cognitive measures an equal number of times (to assess and control for test/retest and placebo improvements).\n\nD' represents 'detectability,' and is a derived statistic which measures a participant's ability to distinguish target stimuli from non-target stimuli, and incorporates response time and accuracy factors. The equation for deriving it is proprietary to the test which markets the CPT. A higher, or less negative, score is considered WORSE.\n\nHRTSD represents the standard deviation of participant hit reaction time data, as measured for a variety of different stimuli types across the trial. It is a measure of the participant's ability to maintain attention across the trial. A higher score represents more variability and is considered WORSE.", 'unitOfMeasure': 'Units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PLEASE NOTE: One participant with epilepsy did not record any usable data for Conners CPT due to pressing the wrong key throughout large portions of the trial. Therefore, he is not included in CPT variables (but is included in other analyses).'}, {'type': 'PRIMARY', 'title': 'Symbol-digit Matching Test (Open Label Phase)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'categories': [{'measurements': [{'value': '48.1', 'spread': '11.6', 'groupId': 'OG000'}, {'value': '53.8', 'spread': '12.0', 'groupId': 'OG001'}, {'value': '55.9', 'spread': '9.2', 'groupId': 'OG002'}, {'value': '60.1', 'spread': '8.9', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.003', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.022', 'groupIds': ['OG002', 'OG003'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.443', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Group x time interaction by 2-way ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'The single-dose double blind phase was followed by an open-label 4-week treatment phase.', 'description': "Symbol-digit matching test is a measure processing speed and working memory. The task involves matching nonsense symbols with numbers based on a key as quickly as possible within 90s. Score represents the number of correct responses within the time frame. Minimum score is 0. There is not a meaningful 'maximum' score, as there are too many symbols for a participant to successfully complete within the allotted time. A higher score is better.", 'unitOfMeasure': 'points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'MCG (Open-label Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'categories': [{'measurements': [{'value': '18.6', 'spread': '13.4', 'groupId': 'OG000'}, {'value': '30.5', 'spread': '14.7', 'groupId': 'OG001'}, {'value': '32.7', 'spread': '16.3', 'groupId': 'OG002'}, {'value': '44.9', 'spread': '19.6', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.004', 'groupIds': ['OG002', 'OG003'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.906', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Between-groups analysis by 2-way ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'The single-dose double blind phase was followed by an open-label 4-week treatment phase.', 'description': 'MCG paragraph memory test is a measure verbal memory. Participants are read aloud a long, detailed story, and are then asked to immediately repeat all information they can remember from the story. Each pertinent story element (as pre-defined on a key) is considered 1 correct response. Minimum score is 0, maximum is 100. A higher score is better.', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Seizure Frequency (Open-label Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)'}], 'classes': [{'categories': [{'measurements': [{'value': '2.8', 'spread': '6.2', 'groupId': 'OG000'}, {'value': '2.4', 'spread': '5.7', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.274', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Randomized portion is followed by 1-month open-label portion.', 'description': "Seizures per 28 'at-risk' days. This is a comparison of 28 days prior to baseline visit as compared to seizure rate while taking methylphenidate, adjusted to provide a 'number of seizures per 28 days' measurement.", 'unitOfMeasure': 'Seizures per 28 at-risk days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'This analysis only compares the 28 participants who were present in both groups. Participants who participated only in the double-blind portion are represented in that analysis.'}, {'type': 'PRIMARY', 'title': 'QOLIE-89 Aggregate Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)', 'description': 'Note: Because the QOLIE-89 is specific to epilepsy populations, most of its questions are not applicable to healthy controls, and therefore healthy controls did not complete the QOLIE-89.'}], 'classes': [{'categories': [{'measurements': [{'value': '60.2', 'spread': '17.1', 'groupId': 'OG000'}, {'value': '72.0', 'spread': '16.2', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Change from baseline to end of methylphenidate open label treatment (end month 2)', 'description': 'QOLIE-89 is a questionnaire to assess quality of life and subjective cognitive effects. The aggregate score is the overall calculated score. Note: most of its questions are specific to patients with epilepsy, and therefore the questionnaire cannot be validly completed by healthy controls. Therefore, only participants with epilepsy completed the questionnaire.\n\nQOLIE aggregate scores and subscale scores are calculated based on individual patient responses throughout the survey, and according to scoring rules as determined by the creator of the questionnaire. Scores are rated 0 (worst) to 100 (best).', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'CPT Scores (Double-blind Portion) (Secondary Variables)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'title': 'Hits', 'categories': [{'measurements': [{'value': '285.3', 'spread': '4.5', 'groupId': 'OG000'}, {'value': '286.9', 'spread': '1.6', 'groupId': 'OG001'}, {'value': '287', 'spread': '2.7', 'groupId': 'OG002'}]}]}, {'title': 'Omissions', 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.5', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '0.4', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '0.8', 'groupId': 'OG002'}]}]}, {'title': 'Commissions', 'categories': [{'measurements': [{'value': '24', 'spread': '19.9', 'groupId': 'OG000'}, {'value': '21.5', 'spread': '18.2', 'groupId': 'OG001'}, {'value': '21.2', 'spread': '15.1', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.04', 'groupIds': ['OG000', 'OG001', 'OG002'], 'pValueComment': 'Hits p = 0.04', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.038', 'groupIds': ['OG000', 'OG001', 'OG002'], 'pValueComment': 'Omissions p = 0.038', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.329', 'groupIds': ['OG000', 'OG001', 'OG002'], 'pValueComment': 'Commissions p = 0.329', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.876', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Hits 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.932', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Omissions 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.898', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Commissions 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Difference between scores on MPH 20mg, 10mg, or placebo during randomized visits weeks 2, 3, or 4', 'description': 'Secondary variables in CPT: hits, omissions, commissions\n\n"Hits" represents the raw number of accurate responses to target stimuli, out of a maximum of 288. A higher number is better.\n\n"Omissions" are errors committed when a target stimuli is not appropriately responded to. A higher number is worse. Theoretically, the maximum number of omissions would be 288. A lower number is BETTER.\n\n"Commissions" are errors committed when a participant responds to a non-target stimuli. Because a participant may make multiple such errors for a given stimuli, there is no raw maximum. A lower number is BETTER.', 'unitOfMeasure': 'Units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Seizure Frequency/Severity (Double-blind Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Double-blind Portion)'}], 'classes': [{'categories': [{'measurements': [{'value': '2.5', 'spread': '5.9', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '5.5', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.7116', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Comparison of baseline rate of seizures (expressed as seizures per 28 days) pre-trial against the rate experienced during the double-blind portion of our trial.', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Seizure rate during 28 days prior to study compared to during randomized, single-dose portion, rate adjusted to seizures per 28 patient days.', 'description': "Seizures per 28 'at-risk' days. This is a comparison of 28 days prior to baseline visit as compared to seizure rate while taking methylphenidate, adjusted to provide a 'number of seizures per 28 days' measurement.", 'unitOfMeasure': 'Seizures per 28 at-risk days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only participants who were present in both groups are included here.'}, {'type': 'SECONDARY', 'title': 'QOLIE-89 Selected Cognitive Subscales (Open-label)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)', 'description': 'Note: Because the QOLIE-89 is specific to epilepsy populations, most of its questions are not applicable to healthy controls, and therefore healthy controls did not complete the QOLIE-89.'}], 'classes': [{'title': 'Attention/Concentration', 'categories': [{'measurements': [{'value': '50.4', 'spread': '21.4', 'groupId': 'OG000'}, {'value': '74.8', 'spread': '19.5', 'groupId': 'OG001'}]}]}, {'title': 'Memory', 'categories': [{'measurements': [{'value': '36.8', 'spread': '27.0', 'groupId': 'OG000'}, {'value': '59.7', 'spread': '26.3', 'groupId': 'OG001'}]}]}, {'title': 'Language', 'categories': [{'measurements': [{'value': '58.1', 'spread': '27.0', 'groupId': 'OG000'}, {'value': '72.3', 'spread': '21.9', 'groupId': 'OG001'}]}]}, {'title': 'Energy/Fatigue', 'categories': [{'measurements': [{'value': '45.9', 'spread': '21.2', 'groupId': 'OG000'}, {'value': '61.6', 'spread': '19.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Attention/Concentration subscale', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Memory subscale', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.002', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Language subscale', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Energy/fatigue subscale', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Comparing baseline (visit 1) to end of open-label (end of week 8)', 'description': 'Pre-selected secondary variables were cognitive subscales on the QOLIE-89 felt likely to be affected by MPH: attention/concentration; memory; language; energy/fatigue.\n\nQOLIE aggregate scores and subscale scores are calculated based on individual patient responses throughout the survey, and according to scoring rules as determined by the creator of the questionnaire. Scores are rated 0 (worst) to 100 (best).', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'CPT Outcomes (Secondary Variables) (Open-label Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'title': 'Hits', 'categories': [{'measurements': [{'value': '284.6', 'spread': '5.1', 'groupId': 'OG000'}, {'value': '287.6', 'spread': '0.9', 'groupId': 'OG001'}, {'value': '287', 'spread': '1.2', 'groupId': 'OG002'}, {'value': '287.6', 'spread': '0.7', 'groupId': 'OG003'}]}]}, {'title': 'Omissions', 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.4', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '0.3', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '0.3', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '0.2', 'groupId': 'OG003'}]}]}, {'title': 'Commissions', 'categories': [{'measurements': [{'value': '34.8', 'spread': '18.4', 'groupId': 'OG000'}, {'value': '18.5', 'spread': '17.8', 'groupId': 'OG001'}, {'value': '16.7', 'spread': '9.7', 'groupId': 'OG002'}, {'value': '13.2', 'spread': '16.1', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.003', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Hits v1 vs v5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.033', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Hits v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.079', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': '2-way ANOVA epilepsy vs healthy hits', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Omissions epilepsy v1 vs v5', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.029', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Omissions v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.048', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Epilepsy v healthy ANOVA Omissions', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Commissions v1 vs v5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.42', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Commissions v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.019', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Healthy vs epilepsy ANOVA (2-way) commissions', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'Omissions, commissions, and hits\n\n"Hits" represents the raw number of accurate responses to target stimuli, out of a maximum of 288. A higher number is better.\n\n"Omissions" are errors committed when a target stimuli is not appropriately responded to. A higher number is worse. Theoretically, the maximum number of omissions would be 288. A lower number is BETTER.\n\n"Commissions" are errors committed when a participant responds to a non-target stimuli. Because a participant may make multiple such errors for a given stimuli, there is no raw maximum. A lower number is BETTER.', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Note: one epilepsy participant's CPT data was invalid/unusable due to pressing the wrong button during the trial."}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Adverse Events Profile (Open-Label)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)', 'description': 'Note: Because the questionnaire is specific to epilepsy populations, and the side-effects to AEDs, healthy controls did not complete the QOLIE-89.'}], 'classes': [{'categories': [{'measurements': [{'value': '41.9', 'spread': '8.5', 'groupId': 'OG000'}, {'value': '34.4', 'spread': '9.6', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'This is a side-effects reporting scale for anti-epileptic medications. Because it encompasses cognitive and non-cognitive side effects, it was not considered one of our main cognitive/quality of life outcomes of interest. It is used in other studies of AED side effects, however, so was included.\n\nThe scale consists of 19 symptoms rated 1 (Never a problem) to 4 (Always or often a problem). Minimum score is 19, maximum score is 76. A higher score is WORSE.', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Stimulant Side-effects Checklist', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)', 'description': 'Note: Because the SSC is specific to medication side effects, healthy controls did not complete the questionnaire.'}], 'classes': [{'categories': [{'measurements': [{'value': '37.2', 'spread': '21.0', 'groupId': 'OG000'}, {'value': '27.3', 'spread': '23.1', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.003', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'Note: Stimulant side-effect score \\*decreased\\* with addition of open-label stimulant.', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'This is a questionnaire covering common stimulant side-effects, intended to help monitor for any significant or common adverse effects.\n\nThe scale lists 16 common stimulant side effects rated 0 (absent) to 9 (serious). Minimum score is 0, maximum is 144. A higher score is WORSE.', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Neuropsychiatric Questionnaires', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'title': 'BDI', 'categories': [{'measurements': [{'value': '9.6', 'spread': '7.3', 'groupId': 'OG000'}, {'value': '6.4', 'spread': '6.1', 'groupId': 'OG001'}, {'value': '2.0', 'spread': '1.7', 'groupId': 'OG002'}, {'value': '1.1', 'spread': '1.5', 'groupId': 'OG003'}]}]}, {'title': 'BAI', 'categories': [{'measurements': [{'value': '10.9', 'spread': '11.1', 'groupId': 'OG000'}, {'value': '9.6', 'spread': '9.2', 'groupId': 'OG001'}, {'value': '2.4', 'spread': '5.1', 'groupId': 'OG002'}, {'value': '1.7', 'spread': '2.1', 'groupId': 'OG003'}]}]}, {'title': 'AES', 'categories': [{'measurements': [{'value': '31.2', 'spread': '5.6', 'groupId': 'OG000'}, {'value': '28.7', 'spread': '7.0', 'groupId': 'OG001'}, {'value': '23.3', 'spread': '5.0', 'groupId': 'OG002'}, {'value': '22.9', 'spread': '4.7', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.014', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'BDI epilepsy v1 vs v5', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.04', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Healthy controls BDI v1 vs v5', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.191', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Between-group comparison 2-way ANOVA BDI', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.42', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'BAI visit 1 vs visit 5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.477', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'BAI visit 1 vs visit 5 healthy controls', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.792', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Between-groups comparison 2-way ANOVA BAI', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.045', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'AES visit 1 vs visit 5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.646', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'AES visit 1 vs visit 5 healthy controls', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.222', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Between-groups comparison 2-way ANOVA AES', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'Beck Depression Inventory, Beck Anxiety Inventory, Apathy Evaluation Scale. These were not primary or secondary variables of interest given methylphenidate\'s primary expected action being on cognition. Included given one author\'s interest, as other studies suggesting psychiatric improvements (particularly apathy and depression) with methylphenidate.\n\nBDI is a common clinical and research measure of depression. It has 21 questions and is scored 0 (no depression) to 63 (most severe depression). A higher score is worse.\n\nBAI is a measure of anxiety, which also has 21 questions and is scored 0 (no anxiety) to 63 (most severe anxiety). A higher score is worse.\n\nAES is a measure of clinical apathy, and is an 18-item scale. It rates symptoms as "not at all," "slightly," "somewhat," or "a lot," which are then converted to numerical values 1 (least apathy) to 4 (most apathy). Scores range from 18 (no apathy) to 72 (most apathy).', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'QOLIE-89 Additional Subscales (Open-label)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy (Baseline)', 'description': 'Participants will receive three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and will complete cognitive testing and neuropsychiatric questionnaires. This single-dose phase will be followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy (Open-label Portion)', 'description': 'Note: Because the QOLIE-89 is specific to epilepsy populations, most of its questions are not applicable to healthy controls, and therefore healthy controls did not complete the QOLIE-89.'}], 'classes': [{'title': 'Health Perceptions', 'categories': [{'measurements': [{'value': '55.2', 'spread': '21.4', 'groupId': 'OG000'}, {'value': '63.4', 'spread': '22.4', 'groupId': 'OG001'}]}]}, {'title': 'Overall QOL (pt rating)', 'categories': [{'measurements': [{'value': '65.5', 'spread': '18.4', 'groupId': 'OG000'}, {'value': '73.0', 'spread': '14.3', 'groupId': 'OG001'}]}]}, {'title': 'Physical Function', 'categories': [{'measurements': [{'value': '78.0', 'spread': '27.4', 'groupId': 'OG000'}, {'value': '83.2', 'spread': '22.4', 'groupId': 'OG001'}]}]}, {'title': 'Role Limitations (Emotional)', 'categories': [{'measurements': [{'value': '67.8', 'spread': '43.0', 'groupId': 'OG000'}, {'value': '79.3', 'spread': '30.0', 'groupId': 'OG001'}]}]}, {'title': 'Role Limitations (Physical)', 'categories': [{'measurements': [{'value': '62.8', 'spread': '36.4', 'groupId': 'OG000'}, {'value': '82.8', 'spread': '30.6', 'groupId': 'OG001'}]}]}, {'title': 'Pain', 'categories': [{'measurements': [{'value': '70.4', 'spread': '30.9', 'groupId': 'OG000'}, {'value': '78.1', 'spread': '22.8', 'groupId': 'OG001'}]}]}, {'title': 'Work/Driving/Social', 'categories': [{'measurements': [{'value': '61.1', 'spread': '27.0', 'groupId': 'OG000'}, {'value': '69.5', 'spread': '22.4', 'groupId': 'OG001'}]}]}, {'title': 'Emotional Wellbeing', 'categories': [{'measurements': [{'value': '70.3', 'spread': '17.0', 'groupId': 'OG000'}, {'value': '75.1', 'spread': '17.8', 'groupId': 'OG001'}]}]}, {'title': 'Health Discouragement', 'categories': [{'measurements': [{'value': '66.4', 'spread': '30.8', 'groupId': 'OG000'}, {'value': '81.8', 'spread': '21.3', 'groupId': 'OG001'}]}]}, {'title': 'Seizure Worry', 'categories': [{'measurements': [{'value': '55.5', 'spread': '28.9', 'groupId': 'OG000'}, {'value': '61.9', 'spread': '31.7', 'groupId': 'OG001'}]}]}, {'title': 'Medication Effects', 'categories': [{'measurements': [{'value': '48.1', 'spread': '28.7', 'groupId': 'OG000'}, {'value': '50.9', 'spread': '30.9', 'groupId': 'OG001'}]}]}, {'title': 'Social Support', 'categories': [{'measurements': [{'value': '71.2', 'spread': '23.4', 'groupId': 'OG000'}, {'value': '73.0', 'spread': '24.5', 'groupId': 'OG001'}]}]}, {'title': 'Social Isolation', 'categories': [{'measurements': [{'value': '74.6', 'spread': '27.6', 'groupId': 'OG000'}, {'value': '81.4', 'spread': '21.4', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.011', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Health Perceptions', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.01', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Overall QOL (subjectively rated by participants on the scale)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.164', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Physical Function', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.065', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Role Limitations (Emotional)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.014', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Role Limitations (Physical)', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.128', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Pain', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.026', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Work/Driving/Social', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.077', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Emotional Wellbeing', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.007', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Health Discouragement', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.063', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Seizure Worry', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.609', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Medication Effects', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.626', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Social Support', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.103', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Social Isolation', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Visit 1 (baseline) vs end of open-label (week 8)', 'description': 'These are the remaining subscales of the QOLIE-89. These were not pre-specified variables of interest or intentional post-hoc analyses, but are automatically calculated in scoring the QOLIE-89 and are included ONLY for completeness of data submission.\n\nQOLIE aggregate scores and subscale scores are calculated based on individual patient responses throughout the survey, and according to scoring rules as determined by the creator of the questionnaire. Scores are rated 0 (worst) to 100 (best).', 'unitOfMeasure': 'Points', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Remaining CPT Variables (Open-label)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'title': 'Variability (units)', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.02', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.008', 'groupId': 'OG001'}, {'value': '0.042', 'spread': '0.01', 'groupId': 'OG002'}, {'value': '0.035', 'spread': '0.009', 'groupId': 'OG003'}]}]}, {'title': 'Perseverations (units)', 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.5', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.2', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '0.0', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Variability v1 vs v5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.096', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Variability v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.136', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Variability 2-way ANOVA healthy vs epilepsy', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.17', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Perseverations v1 vs v5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.104', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'Perseverations v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.661', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'Perseverations 2-way ANOVA healthy vs epilepsy', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline vs end of open-label (week 8)', 'description': 'These are automatically-calculated CPT variables which were not pre-specified variables of interest or intentional post-hoc analyses. They are included ONLY for completeness of data. They include hit reaction time (HRT), variability (VAR), and perseverations (PRS).\n\nHit reaction time represents to the average number of milliseconds required for a participant to respond to target stimuli. There are no meaningful absolute minimum or maximum scores, though 101ms is the current fastest verified response time per our review. A higher score is WORSE.\n\nVariability refers to variations in response time across individual blocks of time within the trial. It differs from HRTSD in that HRTSD measures variability across the entire trial. Minimum is 0. There are no absolute maximums. A higher score is WORSE.\n\nPerseverations are errors made either faster than physiologically possible (\\<100ms). Minimum is 0, there is no maximum. Higher scores are WORSE.', 'unitOfMeasure': 'Units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Note: One participant's CPT data was invalid"}, {'type': 'POST_HOC', 'title': 'Remaining CPT Variables (Double-blind Portion)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'title': 'Variability (units)', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.02', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.01', 'groupId': 'OG001'}, {'value': '0.04', 'spread': '0.01', 'groupId': 'OG002'}]}]}, {'title': 'Perseverations (units)', 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.2', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.2', 'groupId': 'OG001'}, {'value': '0.04', 'spread': '0.1', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.397', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Variability ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.745', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Perseverations ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.362', 'groupIds': ['OG001', 'OG002'], 'groupDescription': '10mg vs 20mg variability', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.745', 'groupIds': ['OG001', 'OG002'], 'groupDescription': '10mg vs 20mg perseverations', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Placebo vs 10mg vs 20mg (visits 2, 3, 4)', 'description': 'Remaining CPT variables are automatically calculated by the program. They were not pre-specified variables of interest nor intentional post-hoc analyses. They are included ONLY for completeness of data submission.\n\nHit reaction time represents to the average number of milliseconds required for a participant to respond to target stimuli. There are no meaningful absolute minimum or maximum scores, though 101ms is the current fastest verified response time per our review. A higher score is WORSE.\n\nVariability refers to variations in response time across individual blocks of time within the trial. It differs from HRTSD in that HRTSD measures variability across the entire trial. Minimum is 0. There are no absolute maximums. A higher score is WORSE.\n\nPerseverations are errors made either faster than physiologically possible (\\<100ms). Minimum is 0, there is no maximum. Higher scores are WORSE.', 'unitOfMeasure': 'Units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Hit Reaction Time (Double Blind)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Placebo', 'description': 'Methylphenidate: Participants received blinded, single-dose capsules during either visit 2, 3, or 4. During one of these visits, they received the placebo capsule.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Methylphenidate 10 mg Dose', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 10 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'OG002', 'title': 'Participants With Epilepsy: Methylphenidate 20 mg', 'description': 'Participants received blinded, single-dose capsules of during visits 2, 3, and 4. During one of these visits, they received the methylphenidate 20 mg dose.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}], 'classes': [{'categories': [{'measurements': [{'value': '437.4', 'spread': '68.9', 'groupId': 'OG000'}, {'value': '433.9', 'spread': '65.2', 'groupId': 'OG001'}, {'value': '435.6', 'spread': '68.9', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.48', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'HRT ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.793', 'groupIds': ['OG001', 'OG002'], 'groupDescription': 'HRT 10mg vs 20mg', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Visits 2 vs 3 vs 4 on randomized medication doses.', 'description': 'Hit reaction time represents the average number of milliseconds required for a participant to respond to target stimuli. There are no meaningful absolute minimum or maximum scores, though 101ms is the current fastest verified response time per our review. A higher score is WORSE.\n\nThis was not a pre-specified variable or an intentional post-hoc analysis, but it is calculated automatically and included here only for completeness of data submission.', 'unitOfMeasure': 'ms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Hit Reaction Time (Open-Label)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Participants With Epilepsy: Visit 1 (Baseline)', 'description': 'At visit 1, participants underwent neurocognitive batteries and neuropsychiatric questionnaires for baseline assessment. No medications were given at this visit.'}, {'id': 'OG001', 'title': 'Participants With Epilepsy: Visit 5 (Open Label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'OG002', 'title': 'Healthy Controls: Visit 1 (Baseline)', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'OG003', 'title': 'Healthy Controls: Visit 5', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}], 'classes': [{'categories': [{'measurements': [{'value': '431.2', 'spread': '69.4', 'groupId': 'OG000'}, {'value': '425.7', 'spread': '60.2', 'groupId': 'OG001'}, {'value': '447.7', 'spread': '62.2', 'groupId': 'OG002'}, {'value': '423.4', 'spread': '63.3', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.5', 'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HRT v1 vs v5 epilepsy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.075', 'groupIds': ['OG002', 'OG003'], 'groupDescription': 'HRT v1 vs v5 healthy', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}, {'pValue': '0.2', 'groupIds': ['OG000', 'OG001', 'OG002', 'OG003'], 'groupDescription': 'HRT epilepsy vs healthy ANOVA', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Visits 2 vs 3 vs 4 on randomized medication doses.', 'description': 'Hit reaction time represents the average number of milliseconds required for a participant to respond to target stimuli. There are no meaningful absolute minimum or maximum scores, though 101ms is the current fastest verified response time per our review. A higher score is WORSE.\n\nThis was not a pre-specified variable or an intentional post-hoc analysis, but it is calculated automatically and included here only for completeness of data submission.', 'unitOfMeasure': 'Milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Participants With Epilepsy (Open-label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'FG001', 'title': 'Healthy Controls', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'id': 'FG002', 'title': '10mg, 20mg, Then Placebo (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG003', 'title': '10mg, Placebo, Then 20mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG004', 'title': 'Placebo, 20mg, Then 10mg (Double-blind', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG005', 'title': 'Placebo, 10mg, Then 20mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG006', 'title': '20mg, Placebo, Then 10mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG007', 'title': '20mg, 10mg, Then Placebo - Double-blind', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.'}, {'id': 'FG008', 'title': '40mg, 20mg, Then Placebo (One Participant)', 'description': 'This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.'}], 'periods': [{'title': 'Double Blind', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '16'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '5'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '15'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '5'}, {'groupId': 'FG006', 'numSubjects': '5'}, {'groupId': 'FG007', 'numSubjects': '4'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}]}]}, {'title': 'Open Label', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': '2 declined to join open-label. 1 withdrew from double-blind but rejoined open-label due to benefit.', 'groupId': 'FG000', 'numSubjects': '30'}, {'comment': 'One was lost to follow-up after completion of visit 4.', 'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '28'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'Participants were enrolled primarily through the Stanford Neurology and Neuropsychiatry clinics between August 2014 and July 2015.', 'preAssignmentDetails': "4 participants signed their consent form, but did not complete any study visits and therefore produced no study data. Therefore, 55 participants are 'enrolled,' but only 51 actually participated in the study flow."}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'BG000'}, {'value': '16', 'groupId': 'BG001'}, {'value': '51', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Participants With Epilepsy', 'description': 'Participants received three single doses of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time. Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After four weeks, their scores on the batteries and questionnaires were again assessed.'}, {'id': 'BG001', 'title': 'Healthy Controls', 'description': 'Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '37', 'groupId': 'BG000', 'lowerLimit': '20', 'upperLimit': '64'}, {'value': '45', 'groupId': 'BG001', 'lowerLimit': '22', 'upperLimit': '62'}, {'value': '39.5', 'groupId': 'BG002', 'lowerLimit': '20', 'upperLimit': '64'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '29', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Mean years of education', 'classes': [{'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000', 'lowerLimit': '12', 'upperLimit': '20'}, {'value': '15', 'groupId': 'BG001', 'lowerLimit': '12', 'upperLimit': '18'}, {'value': '15', 'groupId': 'BG002', 'lowerLimit': '12', 'upperLimit': '20'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Mean duration of epilepsy', 'classes': [{'categories': [{'measurements': [{'value': '12.5', 'groupId': 'BG000', 'lowerLimit': '1', 'upperLimit': '41'}, {'value': '0', 'groupId': 'BG001', 'lowerLimit': '0', 'upperLimit': '0'}, {'value': 'NA', 'comment': 'Healthy controls do not have epilepsy.', 'groupId': 'BG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Seizure type', 'classes': [{'title': 'Focal', 'categories': [{'measurements': [{'value': '26', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}]}]}, {'title': 'Generalized', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}]}, {'title': 'Unclassified (GTCS)', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}], 'populationDescription': 'Total number of individuals who signed consents = 55. 4 of these individuals with epilepsy signed their consent but did not follow through and participate in the study. The remaining 51 (35 epilepsy, 16 controls) are represented here.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 55}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-04', 'completionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-04-26', 'studyFirstSubmitDate': '2014-06-24', 'resultsFirstSubmitDate': '2016-06-04', 'studyFirstSubmitQcDate': '2014-06-27', 'lastUpdatePostDateStruct': {'date': '2017-05-30', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2016-07-19', 'studyFirstPostDateStruct': {'date': '2014-07-01', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-08-31', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Adverse Events Profile (Open-Label)', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'This is a side-effects reporting scale for anti-epileptic medications. Because it encompasses cognitive and non-cognitive side effects, it was not considered one of our main cognitive/quality of life outcomes of interest. It is used in other studies of AED side effects, however, so was included.\n\nThe scale consists of 19 symptoms rated 1 (Never a problem) to 4 (Always or often a problem). Minimum score is 19, maximum score is 76. A higher score is WORSE.'}, {'measure': 'Stimulant Side-effects Checklist', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'This is a questionnaire covering common stimulant side-effects, intended to help monitor for any significant or common adverse effects.\n\nThe scale lists 16 common stimulant side effects rated 0 (absent) to 9 (serious). Minimum score is 0, maximum is 144. A higher score is WORSE.'}, {'measure': 'Neuropsychiatric Questionnaires', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'Beck Depression Inventory, Beck Anxiety Inventory, Apathy Evaluation Scale. These were not primary or secondary variables of interest given methylphenidate\'s primary expected action being on cognition. Included given one author\'s interest, as other studies suggesting psychiatric improvements (particularly apathy and depression) with methylphenidate.\n\nBDI is a common clinical and research measure of depression. It has 21 questions and is scored 0 (no depression) to 63 (most severe depression). A higher score is worse.\n\nBAI is a measure of anxiety, which also has 21 questions and is scored 0 (no anxiety) to 63 (most severe anxiety). A higher score is worse.\n\nAES is a measure of clinical apathy, and is an 18-item scale. It rates symptoms as "not at all," "slightly," "somewhat," or "a lot," which are then converted to numerical values 1 (least apathy) to 4 (most apathy). Scores range from 18 (no apathy) to 72 (most apathy).'}], 'primaryOutcomes': [{'measure': "Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables)", 'timeFrame': 'difference in scores on specific variables between MPH 20mg, 10mg, and placebo (randomized to administration at weeks 2, 3, or 4)', 'description': "Scores on this test measure attentiveness/vigilance and response time. Primary measures are: D', HRTSD D' represents 'detectability,' and is a derived statistic which measures a participant's ability to distinguish target stimuli from non-target stimuli, and incorporates response time and accuracy factors. The equation for deriving it is proprietary to the test which markets the CPT. A higher, or less negative, score is considered WORSE.\n\nHRTSD represents the standard deviation of participant hit reaction time data, as measured for a variety of different stimuli types across the trial. It is a measure of the participant's ability to maintain attention across the trial. A higher score represents more variability and is considered WORSE."}, {'measure': 'Symbol-digit Matching Test (Double-blind Portion)', 'timeFrame': 'Difference in scores between MPH 20mg, 10mg, or placebo during double-blind portion during which medication was randomized to weeks 2, 3, or 4.', 'description': "Symbol-digit matching test is a measure processing speed and working memory. The task involves matching nonsense symbols with numbers based on a key as quickly as possible within 90s. Score represents the number of correct responses within the time frame. Minimum score is 0. There is not a meaningful 'maximum' score, as there are too many symbols for a participant to successfully complete within the allotted time. A higher score is better."}, {'measure': 'MCG Paragraph Memory Test (Double-blind Portion)', 'timeFrame': 'Difference in scores between MPH 20mg, 10mg, or placebo, randomized to be given at weeks 2, 3, or 4', 'description': 'MCG paragraph memory test is a measure of verbal memory. Participants are read aloud a long, detailed story, and are then asked to immediately repeat all information they can remember from the story. Each pertinent story element (as pre-defined on a key) is considered 1 correct response. Minimum score is 0, maximum is 100. A higher score is better.'}, {'measure': 'Conners CPT Outcomes (Primary Variables) (Open-Label Portion)', 'timeFrame': 'Difference between scores at baseline (visit 1) and on methylphenidate open-label (visit 5), compared to untreated healthy controls', 'description': "Within-groups comparison (between visit 1 and visit 5 within patients with epilepsy, comparing scores at baseline to scores on methylphenidate) as well as a comparison against healthy controls who repeated the cognitive measures an equal number of times (to assess and control for test/retest and placebo improvements).\n\nD' represents 'detectability,' and is a derived statistic which measures a participant's ability to distinguish target stimuli from non-target stimuli, and incorporates response time and accuracy factors. The equation for deriving it is proprietary to the test which markets the CPT. A higher, or less negative, score is considered WORSE.\n\nHRTSD represents the standard deviation of participant hit reaction time data, as measured for a variety of different stimuli types across the trial. It is a measure of the participant's ability to maintain attention across the trial. A higher score represents more variability and is considered WORSE."}, {'measure': 'Symbol-digit Matching Test (Open Label Phase)', 'timeFrame': 'The single-dose double blind phase was followed by an open-label 4-week treatment phase.', 'description': "Symbol-digit matching test is a measure processing speed and working memory. The task involves matching nonsense symbols with numbers based on a key as quickly as possible within 90s. Score represents the number of correct responses within the time frame. Minimum score is 0. There is not a meaningful 'maximum' score, as there are too many symbols for a participant to successfully complete within the allotted time. A higher score is better."}, {'measure': 'MCG (Open-label Portion)', 'timeFrame': 'The single-dose double blind phase was followed by an open-label 4-week treatment phase.', 'description': 'MCG paragraph memory test is a measure verbal memory. Participants are read aloud a long, detailed story, and are then asked to immediately repeat all information they can remember from the story. Each pertinent story element (as pre-defined on a key) is considered 1 correct response. Minimum score is 0, maximum is 100. A higher score is better.'}, {'measure': 'Seizure Frequency (Open-label Portion)', 'timeFrame': 'Randomized portion is followed by 1-month open-label portion.', 'description': "Seizures per 28 'at-risk' days. This is a comparison of 28 days prior to baseline visit as compared to seizure rate while taking methylphenidate, adjusted to provide a 'number of seizures per 28 days' measurement."}, {'measure': 'QOLIE-89 Aggregate Score', 'timeFrame': 'Change from baseline to end of methylphenidate open label treatment (end month 2)', 'description': 'QOLIE-89 is a questionnaire to assess quality of life and subjective cognitive effects. The aggregate score is the overall calculated score. Note: most of its questions are specific to patients with epilepsy, and therefore the questionnaire cannot be validly completed by healthy controls. Therefore, only participants with epilepsy completed the questionnaire.\n\nQOLIE aggregate scores and subscale scores are calculated based on individual patient responses throughout the survey, and according to scoring rules as determined by the creator of the questionnaire. Scores are rated 0 (worst) to 100 (best).'}], 'secondaryOutcomes': [{'measure': 'CPT Scores (Double-blind Portion) (Secondary Variables)', 'timeFrame': 'Difference between scores on MPH 20mg, 10mg, or placebo during randomized visits weeks 2, 3, or 4', 'description': 'Secondary variables in CPT: hits, omissions, commissions\n\n"Hits" represents the raw number of accurate responses to target stimuli, out of a maximum of 288. A higher number is better.\n\n"Omissions" are errors committed when a target stimuli is not appropriately responded to. A higher number is worse. Theoretically, the maximum number of omissions would be 288. A lower number is BETTER.\n\n"Commissions" are errors committed when a participant responds to a non-target stimuli. Because a participant may make multiple such errors for a given stimuli, there is no raw maximum. A lower number is BETTER.'}, {'measure': 'Seizure Frequency/Severity (Double-blind Portion)', 'timeFrame': 'Seizure rate during 28 days prior to study compared to during randomized, single-dose portion, rate adjusted to seizures per 28 patient days.', 'description': "Seizures per 28 'at-risk' days. This is a comparison of 28 days prior to baseline visit as compared to seizure rate while taking methylphenidate, adjusted to provide a 'number of seizures per 28 days' measurement."}, {'measure': 'QOLIE-89 Selected Cognitive Subscales (Open-label)', 'timeFrame': 'Comparing baseline (visit 1) to end of open-label (end of week 8)', 'description': 'Pre-selected secondary variables were cognitive subscales on the QOLIE-89 felt likely to be affected by MPH: attention/concentration; memory; language; energy/fatigue.\n\nQOLIE aggregate scores and subscale scores are calculated based on individual patient responses throughout the survey, and according to scoring rules as determined by the creator of the questionnaire. Scores are rated 0 (worst) to 100 (best).'}, {'measure': 'CPT Outcomes (Secondary Variables) (Open-label Portion)', 'timeFrame': 'Baseline (Visit 1) vs end of Open-label (week 8)', 'description': 'Omissions, commissions, and hits\n\n"Hits" represents the raw number of accurate responses to target stimuli, out of a maximum of 288. A higher number is better.\n\n"Omissions" are errors committed when a target stimuli is not appropriately responded to. A higher number is worse. Theoretically, the maximum number of omissions would be 288. A lower number is BETTER.\n\n"Commissions" are errors committed when a participant responds to a non-target stimuli. Because a participant may make multiple such errors for a given stimuli, there is no raw maximum. A lower number is BETTER.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Epilepsy', 'Cognitive Deficits', 'Attention Deficits']}, 'referencesModule': {'references': [{'pmid': '28031390', 'type': 'DERIVED', 'citation': 'Adams J, Alipio-Jocson V, Inoyama K, Bartlett V, Sandhu S, Oso J, Barry JJ, Loring DW, Meador K. Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study. Neurology. 2017 Jan 31;88(5):470-476. doi: 10.1212/WNL.0000000000003564. Epub 2016 Dec 28.'}]}, 'descriptionModule': {'briefSummary': "Methylphenidate (MPH) has long been used to improve attention and cognitive difficulties associated with ADHD, including in children with ADHD and epilepsy (Torres et al., 2008). Methylphenidate (MPH) is also helpful in treating attention and other cognitive difficulties in a variety of other neurological and medical conditions (Kajs-Wyllie, 2002; Prommer, 2012). We seek to evaluate the potential efficacy and safety of this medication in treating attention deficits, as well as other cognitive difficulties, experienced by adult patients with epilepsy.\n\nTo our knowledge, there are currently very few studies which explicitly examine the impact of MPH on measureable attention deficits and other cognitive deficits in adult patients with epilepsy. We hope to quantify what impact, if any, methylphenidate has on attention, in addition to other specific measureable cognitive functions, in patients with cognitive complaints and epilepsy, and contribute to a growing body of evidence which supports the safety of methylphenidate's use for attention deficits in patients with epilepsy. As other effective treatments for attention and other cognitive difficulties in patients with epilepsy are not currently available, MPH could represent an important option in the treatment of such patients.", 'detailedDescription': "Prospective participants with seizures will be identified primarily through the Stanford Neurology and Neuropsychiatry clinics and Stanford Medical Center, with the assistance of clinic staff and providers. Participants may also be identified and referred by their physicians in the community as well. Informational fliers will be distributed to these clinics and throughout Stanford Medical Center and Stanford campus in order to identify participants with epilepsy as well as healthy volunteers. Prospective participants may also contact study staff directly via contact information listed on the flier or provided to them by their providers. Those identified will be contacted, either in person or by telephone, by study staff.\n\nA telephone or in-person pre-screening will occur, expected to last approximately 20-30 minutes, in order to determine eligibility for the study, interest in participating, and any questions related to the study. A brief summary of study procedures and goals will be reviewed during this pre-screening. Participants who meet inclusion/exclusion criteria may take part in an initial in-person visit at Stanford Medical Center, where informed consent will be obtained and signed (see attached informed consent form). Any additional history needed in order to confirm a participant's eligibility will be reviewed at this visit. If the individual chooses to proceed, the participant's blood pressure and heartrate will be measured, and if necessary (because a recent physical exam including cardiac auscultation is not available), a brief physical exam will be performed by a licensed physician. If vital signs and exam (if necessary) are normal, participants will be asked to complete neuropsychiatric questionnaires, self-report questionnaires, a quality-of-life questionnaire, and a seizure diary. The full 40-minute neurocognitive battery will be performed, and baseline scores obtained.\n\nParticipants will be asked to complete the seizure diary once per week, either in-person at their visits or at home. Thereafter, the participant will be asked to attend at least three additional 2-hour sessions at Stanford Medical Center. The participant will be asked to avoid taking any non-routine sedating medications within 24 hours of his/her scheduled visit, and to refrain from eating, drinking caffeine, or smoking for 2 hours prior to his/her visit. When the participant arrives, they will be given either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate (randomized and blinded by the research pharmacy), and asked to remain within the hospital for 1 hour prior to testing to allow the medication to enter their system. Both study staff and the participant will be blinded to whether they are receiving active medication or placebo. During this time, the participant will complete self-report questionnaires reporting any medication changes, medical events, or significant adverse events, and their seizure diary will be reviewed and kept by study staff. After this, the full neurocognitive battery will be completed. Following the completion of neurocognitive testing, the participant's next visit will be scheduled for approximately the same time of day in approximately one week, and payment will be provided. This procedure will be repeated for the next two visits. Participants will not receive any additional study drug during this period other than the single dose they receive in-person.\n\nAt the participant's fourth visit, they will be asked to repeat the neuropsychiatric questionnaires from visit #1, as well as the usual self-report forms and seizure diary. Heartrate and blood pressure will be obtained again prior to the administration of the neurocognitive battery. At the end of the fourth visit, participants will be asked if they wish to take part in the four-week open-label phase of this study, designed to evaluate the ongoing efficacy and safety of methylphenidate for use in patients with epilepsy. Regardless of their answer, payment will be provided for their fourth visit.\n\nThose participants who are interested in participating in the open-label trial will be provided with a prescription for two weeks of methylphenidate 10mg PO BID, followed by two weeks of methylphenidate 20mg PO BID. Participants will be provided with copies of the seizure diary and asked to complete it weekly. Participants will be able to contact the protocol director by phone to report any significant side effects or adverse events during this trial. At the protocol director's discretion, in keeping with standard of care for this medication, the dosage of the medication may be lowered (minimum dose 5mg PO BID) in response to any side effects experienced by participants during this period.\n\nParticipants in the open-label trial will be asked to return after four more weeks for a fifth and final visit. Participants will again be asked to refrain from eating, caffeine, and nicotine for 2 hours prior to their visit, and will take their prescribed methylphenidate upon arriving at Stanford Medical Center. Participants will wait 1 hour for the medication to enter their system, during which time they will complete neuropsychiatric and self-report questionnaires as before, their seizure diaries will be reviewed, and their heart rate and blood pressure will again be measured. The cognitive battery will be administered again. Afterwards, any participant questions will be answered and final financial compensation will be provided, and the participant's involvement has ended. Data will remain blinded until the completion of the study. Participants wishing to receive the active medication following the termination of the open-label phase of the study may do so at the discretion of their physicians."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. For participants with seizures:\n\n * H/o seizures of any cause\n * Subjective cognitive complaints\n * Stable antiepileptic drug doses which are not expected to change during the study\n * Recent normal cardiac auscultation (may be done prior to enrollment by personal physician or study staff)\n * Neurologist's judgement that participant is clinically appropriate for this study\n2. For healthy volunteers\n\n * No history of seizures or other neurological disorders\n * No history of cognitive complaints for any reason (including ADHD)\n * Not on any medications which would interfere w/ cognitive testing\n3. English fluency\n\nExclusion Criteria:\n\n1. IQ\n2. History of an adverse reaction to methylphenidate\n3. Age \\>65 or \\<18\n4. Personal medical history of\n\n 1. Arrhythmias,\n 2. Structural cardiac disease,\n 3. Other cardiac abnormality\n 4. Uncontrolled hypertension (\\>150/95) during study. For those with BP \\>140/90 \\& \\<150/95, they will be monitored during the study and refer them for treatment if their BP remains elevated throughout the study.\n 5. Uncontrolled tachycardia during study\n 6. Progressive neurological disorders which may interfere w/ cognition for reasons other than seizures\n 7. Glaucoma\n 8. Other medical or neurological illnesses or symptoms which may interfere with cognition or medication (e.g., severe liver or renal disease, active infections, etc), or which make use of the medication inappropriate (e.g., severe agitation/anxiety).\n 9. Intellectual disability sufficient to render a participant unable to consent\n 10. Status epilepticus within the last year\n 11. Neurosurgery which would be expected to interfere with study tasks within the last 6 months.\n5. Substance use history\n\n 1. Met criteria for substance use disorder within the past year\n 2. Active illicit substance use\n 3. Alcohol use meeting criteria for substance abuse\n 4. Unwillingness to abstain from alcohol w/in 24 hours of testing\n6. Personal psychiatric history\n\n 1. History of a primary psychotic disorder, such as schizophrenia, or mania.\n 2. History of suicide attempts within the last year\n 3. Active suicidality\n7. Severe cognitive impairments (e.g. aphasia) which render a participant unable to consent\n8. Currently receiving medications which would be expected to interfere with the study tasks, if they cannot be held for study visits;\n9. Pregnancy or active breastfeeding;\n10. Women of childbearing potential who are sexually active and not willing or able to use a contraceptive strategy during the course of the study.\n11. Any other factor which may interfere w/ a participant's ability to consent or to complete the required cognitive tasks, or may significantly interfere with their performance on the required tests\n12. Concomitant use of an MAOI (if receiving methylphenidate during this study), or use of an MAOI within the last 14 days prior to receiving methylphenidate."}, 'identificationModule': {'nctId': 'NCT02178995', 'briefTitle': 'Methylphenidate Treatment of Attention Deficits in Epilepsy', 'organization': {'class': 'OTHER', 'fullName': 'Stanford University'}, 'officialTitle': 'Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy', 'orgStudyIdInfo': {'id': 'MPH in epilepsy'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'NO_INTERVENTION', 'label': 'Healthy Controls', 'description': "Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.\n\nHealthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."}, {'type': 'EXPERIMENTAL', 'label': 'Participants With Epilepsy (Open-label)', 'description': 'Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': '10mg, 20mg, Then Placebo (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': '10mg, Placebo, Then 20mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': 'Placebo, 20mg, Then 10mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': 'Placebo, 10mg, Then 20mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': '20mg, Placebo, Then 10mg (Double-blind)', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': '20mg, 10mg, Then Placebo - Double-blind', 'description': 'Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.\n\nMethylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.', 'interventionNames': ['Drug: Methylphenidate']}, {'type': 'EXPERIMENTAL', 'label': '40mg, 20mg, Then Placebo (One Participant)', 'description': 'This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.', 'interventionNames': ['Drug: Methylphenidate']}], 'interventions': [{'name': 'Methylphenidate', 'type': 'DRUG', 'otherNames': ['Ritalin'], 'description': 'Participants with epilepsy will first receive blinded, single-dose capsules which contain either:\n\nPlacebo 20mg of methylphenidate or 10mg of methylphenidate.\n\nAt each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.', 'armGroupLabels': ['10mg, 20mg, Then Placebo (Double-blind)', '10mg, Placebo, Then 20mg (Double-blind)', '20mg, 10mg, Then Placebo - Double-blind', '20mg, Placebo, Then 10mg (Double-blind)', '40mg, 20mg, Then Placebo (One Participant)', 'Participants With Epilepsy (Open-label)', 'Placebo, 10mg, Then 20mg (Double-blind)', 'Placebo, 20mg, Then 10mg (Double-blind)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94305', 'city': 'Palo Alto', 'state': 'California', 'country': 'United States', 'facility': 'Stanford University', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}], 'overallOfficials': [{'name': 'Jesse M Adams, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Stanford University'}, {'name': 'Kimford Meador, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Stanford University'}, {'name': 'John Barry, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Stanford University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kimford Jay Meador', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Kimford Jay Meador', 'investigatorAffiliation': 'Stanford University'}}}}